Brief: Pherecydes Pharma FY Operating Loss Widens To EUR 4.32 Million

Pherecydes Pharma SA

14/04/2022 07:18

April 14 (Reuters) - Pherecydes Pharma SA  ALPHE.PA :
    * PHERECYDES PHARMA ANNOUNCES ITS 2021 ANNUAL FINANCIAL
RESULTS
AND CONFIRMS ITS 2022 OUTLOOK
    * FY OPERATING LOSS ROSE 26 PERCENT TO -4.32 MILLION EUR
    * CASH POSITION OF €5.4 MILLION AT DECEMBER 31, 2021
    * SIGNIFICANT ACCELERATION IN COMPASSIONATE TREATMENT,
TAKING
NUMBER OF PATIENTS TREATED WITH PHERECYDES PHARMA PHAGES THUS
FAR TO 50
    * APPROVAL GRANTED TO INITIATE THE PHAGODAIR PHASE I/II
CLINICAL
TRIAL, ENROLLMENT OF THE FIRST PATIENT IN THE COMING WEEKS
    * AAC EARLY ACCESS PROGRAM APPROVAL EXPECTED DURING Q2 2022
    * AT DECEMBER 31, 2021, TOTAL OPERATING INCOME, ESSENTIALLY
CONSISTING OF CAPITALIZED PRODUCTION ASSOCIATED WITH
STAPHYLOCOCCUS AUREUS (S. AUREUS) AND PSEUDOMONAS AERUGINOSA (P.
AERUGINOSA) PROGRAMS, WAS EUR 2,200 THOUSAND
    * ANNUAL OPERATING LOSS WAS EUR 4,320 THOUSAND IN 2021,
VERSUS A
LOSS OF EUR 3,426 THOUSAND IN 2020,
    * FY NET LOSS EUR 3.2 MILLION VERSUS LOSS EUR 1.4 MILLION
YEAR AGO
    * IN 2022, COMPANY INTENDS TO CONTINUE DEVELOPMENT OF ITS
RESEARCH
PORTFOLIO'S VARIOUS ASSETS AND ACCELERATE RAMPING UP OF
PRECISION PHAGE THERAPY.
    * PHAGODAIR PHASE I/II CLINICAL STUDY IN BONE-JOINT
INFECTIONS ON
PROTHESIS HAS RECEIVED ALL NECESSARY APPROVALS IN FRANCE, AND
ENROLLMENT OF FIRST PATIENT IS EXPECTED IN Q2 2022
    * AAC SYSTEM (FORMERLY ATU) ALLOWS CERTAIN CATEGORIES OF
SICK
PATIENTS IN FRANCE WITH NO THERAPEUTIC SOLUTIONS TO BENEFIT FROM
DRUGS YET TO RECEIVE MARKETING AUTHORIZATION
    * STRATEGY AND OUTLOOK: CLINICAL DEVELOPMENT OF ANTI-S.
AUREUS
PHAGES, FIRST RESULTS ANTICIPATED DURING THE SUMMER OF 2023
    * STRATEGY AND OUTLOOK: TWO OTHER STUDIES, FUNDED BY PUBLIC
PROGRAMS (PHRC HOSPITAL CLINICAL RESEARCH PROGRAM), SHOULD BE
LAUNCHED IN 2022 WITH PHERECYDES PHARMA’S PHAGES

Source text for Eikon:  urn:newsml:reuters.com:*:nBw1hFJ4ca
Further company coverage:  ALPHE.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))